We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Synthetic peptide fragment (65-76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting.
- Authors
Arefieva, T. I.; Krasnikova, T. L.; Potekhina, A. V.; Ruleva, N. U.; Nikitin, P. I.; Ksenevich, T. I.; Gorshkov, B. G.; Sidorova, M. V.; Bespalova, Zh. D.; Kukhtina, N. B.; Provatorov, S. I.; Noeva, E. A.; Chazov, E. I.
- Abstract
Objective and design: The peptide from C-terminal domain of MCP-1 (Ingramon) has been shown to inhibit monocyte migration and possess anti-inflammatory activity in animal models of inflammation and post-angioplasty restenosis. Here, we investigate the effect of Ingramon treatment on blood levels of acute-phase reactants and chemokines in patients after coronary stenting and the mechanisms of Ingramon anti-inflammatory activity. Subjects: Eighty-seven patients with ischemic heart disease (IHD) who faced the necessity of coronary angiography (CA) were enrolled. In 67 patients, one-stage coronary stenting was performed; 33 of them were treated with Ingramon in addition to standard therapy. Twenty patients underwent CA only. Methods: High-sensitivity C-reactive protein (hsCRP) and fibrinogen blood levels were detected routinely. The chemokine concentration in plasma was measured by enzymelinked immunosorbent assay (ELISA) or cytometric bead array-based immunoassay. Intracellular Ca2+ levels and cell surface integrin exposure were assayed by flow cytometry. MCP-1 dimerization was studied by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDSPAGE). MCP-1-heparin binding was assessed with a biosensor and ELISA. Results and conclusions: Ingramon treatment was accompanied by less pronounced elevation of hsCRP and fibrinogen levels and decreased MCP-1 concentration in plasma in patients after coronary stenting. Ingramon had no effect on MCP-1 interaction with cell receptors or MCP-1 dimerization, but inhibited MCP-1 binding to heparin. The anti-inflammatory activity of the peptide may be mediated by an impaired chemokine interaction with glycosaminoglycans.
- Subjects
C-terminal binding proteins; HEPARIN; ANTI-inflammatory agents; ANGINA pectoris; CORONARY angiography; PATIENTS
- Publication
Inflammation Research, 2011, Vol 60, Issue 10, p955
- ISSN
1023-3830
- Publication type
Article
- DOI
10.1007/s00011-011-0356-z